Plasma miR-221 as a Predictive Biomarker for Chemoresistance in Breast Cancer Patients who Previously Received Neoadjuvant Chemotherapy

Publisher： Karger

E-ISSN： 2296-5262|34|12|675-680

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.12, 2011-11, pp. : 675-680

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 237-242

Karger

Access to resources Recommend Favorite

Correlation between Tumor-Infiltrating Lymphocytes and Pathological Response in Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy in H. Adam Malik General Hospital

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-08 ,pp. : 699-705

Karger

Access to resources Recommend Favorite

Circulating miR‐221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 10, 2010-10 ,pp. : 1674-1680

John Wiley & Sons Inc

Access to resources Recommend Favorite

Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer

By              

International Journal of Molecular Medicine, Vol. 36, Iss. 6, 2015-01 ,pp. : 1720-1726

Spandidos Publications

Access to resources Recommend Favorite

Predictive Factors for Response to Neoadjuvant Therapy in Breast Cancer

By  

Oncology Research and Treatment, Vol. 37, Iss. 10, 2014-09 ,pp. : 563-568

Karger

Access to resources Recommend Favorite